Subscribe To
Ocugen mucosal vaccine candidate ocu500 selected by nih/niaid project nextgen for inclusion in clinical trials
NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms ...
October 10, 2023, 10:30 am
Inhaled nitric oxide delivery system market predicted to reach usd 497.4 million by 2031, expanding at a cagr of 5.4% – exclusive report by transparency market research
An increase in the geriatric population suffering from respiratory conditions is expected to drive the demand for these systems and other advanced med...
September 11, 2023, 3:15 pm
Plarean imaging says medicare code in line with expectations
Polarean Imaging said it has been issued a US reimbursement code for its XENOVIEW lung imaging technology that corresponds to a payment range of betw...
September 5, 2023, 10:22 am
Mannkind corporation announces participation at upcoming conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the develop...
September 5, 2023, 10:00 am
Advent therapeutics awarded $3 million nih grant for novel neonatal lung therapy
Expedites Development of Non-Invasive inhaled Bronchopulmonary Dysplasia Therapy DOYLESTOWN, Pa., July ...
July 18, 2023, 11:30 am
Liquidia corporation and pharmosa biopharm announce collaboration for sustained-release inhaled treprostinil product in north america
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil adm...
June 28, 2023, 9:36 am
Spexis provides business update and announces financial results for the full year 2022
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT ...
May 30, 2023, 5:15 am
Dr. burkhard blank joins mannkind as executive vice president of research & development and chief medical officer
DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of...
May 24, 2023, 12:30 pm
Pulmatrix selected to present at the annual biotechnology innovation organization (bio) international convention
Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXI...
May 24, 2023, 9:05 am
Aerovate therapeutics presents nonclinical pharmacokinetic data in support of av-101, a novel dry powder inhaled formulation of imatinib, at the american thoracic society (ats) 2023 international conf
Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing Formulation impac...
May 22, 2023, 5:15 pm
Verona pharma: revolutionizing copd with first triple mechanism inhaled drug
Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in COPD. Phase 3 data showed that the d...
May 18, 2023, 6:51 pm
Beyond air® schedules fiscal year end 2023 financial results conference call and webcast
GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company f...
May 16, 2023, 4:05 pm
Avalyn pharma showcasing therapeutic approach and clinical status at ats 2023 and the respiratory innovation summit (ris)
– Avalyn CEO to Present in Company Showcase and Moderate Panel Discussion at ATS RIS – – Results from Long-Term Treatment of Pulmonary Fibrosis ...
May 11, 2023, 12:00 pm
Aerami therapeutics to present pharmacokinetic data supporting aer-901 (inhaled imatinib) for pulmonary hypertension at the 2023 american thoracic society (ats) international conference
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing ...
May 11, 2023, 12:00 pm
Verona's ensifentrine: a promising novel treatment for copd patients
Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4,...
March 27, 2023, 2:31 am
Regn stock alert: regeneron pharmaceuticals gains on dupixent drug data
Regeneron Pharmaceuticals (NASDAQ: REGN ) stock is on the rise Thursday after the company released its latest data on Dupixent. Dupixent is a drug can...
March 23, 2023, 10:43 am
Therma bright appoints inhaled drug pioneer dr john patton as chairman of instatin
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF), a developer and investor in a range of proprietary diagnostic and medical technologies, revealed that indus...
March 1, 2023, 10:11 am
Mannkind corporation to participate in the svb securities global biopharma conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the developm...
February 10, 2023, 10:00 pm
Verona pharma: small biotech targeting $10bn copd market with a late stage drug
Verona Pharma is a UK-based biotech with a $1.6Bn market cap developing a phase 3 asset targeting COPD. Ensifentrine is a novel phase 3...
February 7, 2023, 6:01 am
Aerovate: developing an exciting pah drug, initiating with a buy
Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-1...
January 29, 2023, 7:12 am